Modafinil and depression — razumna’s position

This page exists because the question is asked. The answer is that the clinical question belongs to a physician, not to a vendor and not to a self-directed buyer.

The position

Razumna sells generic modafinil. Razumna does not sell modafinil for the treatment of depression, does not recommend it for depression, and does not characterize the drug as effective for depression. The FDA-approved indications are narcolepsy, shift-work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. Depression is not an approved use.

Why the question gets asked

Modafinil produces alertness through a mechanism unrelated to the serotonergic and noradrenergic systems that conventional antidepressants act on. Some physicians have explored its role as an adjunctive option for specific residual symptoms in patients already on antidepressant therapy. That clinical decision belongs to a treating physician evaluating a specific patient, not to a generalized framework, not to a vendor recommendation, and not to a buyer reading about it online.

What is not appropriate

Self-medication of clinical depression. Substituting modafinil for evidence-based depression treatment. Use in patients with bipolar disorder or family history of bipolar disorder, where the documented risk of triggering manic episodes is a stop signal.

If depression is the question, talk to a physician

Razumna is not a clinical service. If a qualified physician decides modafinil belongs in a treatment plan, they will prescribe and monitor it. The right starting point for a depression question is a clinician, not a vendor catalog.

Related

For the FDA-approved indications and standard use cases, see what modafinil is. For the side-effect profile, see modafinil side effects.